Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424226 · ClinicalTrials.gov registry record · Phase 1
Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages
A Phase 1 study of Acute Mountain Sickness, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT03424226: Completed Phase 1 study of Acute Mountain Sickness, sponsored by Stanford University.
NCT03424226 is a Phase 1 study of Acute Mountain Sickness that has completed, run by Stanford University. The registered enrollment target is 105 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03424226, a Phase 1 study of Acute Mountain Sickness, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
This double blind randomized trial will compare acetazolamide taken the morning of ascent to acetazolamide taken the evening prior to ascent for the prevention of acute mountain sickness (AMS). The day of ascent dosing has not been studied as a powered primary outcome. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California
Primary Outcome
incidence of acute mountain sickness by Lake Louise Questionnaire
Conditions Studied
Interventions
- DRUG Acetazolamide
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2018-08-04 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 1 |
What the finished NCT03424226 record still lists
NCT03424226 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher).
The record links to 1 condition, with Acute Mountain Sickness appearing as the primary indexed condition, and to 1 intervention - of which Acetazolamide is the first listed.
NCT03424226 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03424226 about?
NCT03424226 is a clinical study titled "Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages". This double blind randomized trial will compare acetazolamide taken the morning of ascent to acetazolamide taken the evening prior to ascent for the prevention of acute mountain sickness (AMS). The day of ascent dosing has not been studied as a powered primary outcome. The study population is hikers...
What is the current status of trial NCT03424226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2018-08-04. Estimated completion is 2018-09-30.
What conditions does trial NCT03424226 study?
This clinical trial studies the following conditions: Acute Mountain Sickness.
What interventions are being tested in trial NCT03424226?
The interventions under investigation include: Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT03424226?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03424226 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Mountain Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03424226's enrollment target sits among peer trials
105 533rd of 2000 higher than 1,465 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI